tiprankstipranks
Piper Sandler Sticks to Its Sell Rating for Canopy Growth (CGC)
Blurbs

Piper Sandler Sticks to Its Sell Rating for Canopy Growth (CGC)

Piper Sandler analyst Michael Lavery reiterated a Sell rating on Canopy Growth (CGCResearch Report) today and set a price target of $3.00. The company’s shares closed last Friday at $4.02.

Lavery covers the Consumer Defensive sector, focusing on stocks such as Campbell Soup, Post Holdings, and Celsius Holdings. According to TipRanks, Lavery has an average return of 6.8% and a 53.61% success rate on recommended stocks.

Currently, the analyst consensus on Canopy Growth is a Moderate Sell with an average price target of $3.64.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $25.40 and a one-year low of $3.47. Currently, Canopy Growth has an average volume of 2.98M.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CGC in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Canopy Growth (CGC) Company Description:

Canopy Growth Corp. engages in the production and sale of medical cannabis. The company offers products including oils and concentrates, soft gel capsules and hemp. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.

Read More on CGC:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles